The cannabis industry is growing rapidly. With legalization sweeping across North America and the globe, many new companies are sprouting and growing in attempts to cash in on what has become known as the “green gold rush.”
And it’s not just products that contain THC – the chemical that causes a psychoactive “high” – that are making a big market. It’s also products that contain cannabidiol, also known as CBD. CBD doesn’t produce a high yet still gives many positive effects for the user. The compound has medicinal properties and is commonly concentrated into an oil that can be ingested easily.
CBD oil has been shown to help people with everything from severe seizures to mild anxiety. A company that makes high-quality CBD oil is in a position to profit well. Here are some insights into the top CBD oil stocks.
ChineseInvestors.com, Inc. (CIIX)
ChineseInvestors.com, Inc. has been creating brand awareness for its “Opt Hemp” brand in both the Chinese and American markets ever since its creation in April 2017. The company is responsible for both retail and online sales of hemp-based health products in the USA.
In June 2017, the company’s first retail location opened and was called the Chinese Wellness Center. They also work with Medicine Man Denver in an effort to create new intellectual property and intend to provide consulting and licensing services in the cannabis industry.
Aurora Cannabis (ACBFF)
Aurora Cannabis Inc. worked with Micron Waste Technologies to achieve positive results from optimizing the Cannavore technology to process waste products resulting from the cultivation of cannabis. Aurora now plans to optimize the technology and add digitized remote operating functions, at which time Micron will start to offer the units commercially.
GW Pharmaceuticals Plc. (GWPH)
A biopharmaceutical company, GW Pharmaceuticals plc is involved in discovering, developing, and commercializing cannabinoid medicine using cannabis extracts. There are three segments through which the company operates: Pipeline Research and Development, Sativex Research and Development, and Commercial.
The company’s primary product is called Epidiolex, an oral medicine currently in Phase 3 clinical trials for treating childhood epilepsy and other symptoms and syndromes. Another product the company creates and markets is Sativex, an oromucosal spray designed to treat spasticity caused by multiple sclerosis.
Zynerba Pharmaceuticals Inc (ZYNE)
Zynerba focuses its efforts on developing and distributing transdermal (applied via the skin) cannabinoid treatments for rare neuropsychiatric disorders. Some of its current products in development include ZYN002, which has passed Phase 2 clinical trials for adolescent and pediatric patients suffering from fragile X syndrome, epileptic encephalopathies, and adults suffering from refractory epileptic focal seizures, and ZYN001 that is currently going through Phase 1 clinical trials for the treatment of Tourette’s syndrome.
Cara Therapeutics Inc. (CARA)
Cara Therapeutics is working on creating products that target the body’s immune cells and peripheral nervous system. It’s top products include KORSUVA, an injection, which is in Phase 3 trials for treatment of chronic kidney disease, and also in Phase 2 trials for treating dialysis patients who struggle with uremic pruritus.
The company also continues to develop Oral KORSUVA, which has completed Phase 1 clinical trials for treating uremic pruritus, chronic kidney disease, and pruritus chronic liver disease. Another product in development at Cara is CR845, an injection in Phase 3 trials that is intended to treat acute postoperative pain, as well as other variations of the drug designed to treat other specific forms of pain.
The company is licensed with Maruishi Pharmaceutical Co., Ltd to create and distribute pharmaceuticals containing CR845 for pain and pruritus in Japan.
As you can see, CBD oil stocks can be a little tricky. Unlike the typical cannabis company, companies that specialize in CBD oil are often involved in developing all sorts of unique pharmaceutical products. These drugs take time to formulate, and then they have to make their way through clinical trials before they can hit the market.
This makes the CBD oil business somewhat more complicated than the business of cultivating, harvesting, and selling marijuana flower (the product most recreational users smoke). However, these companies could wind up becoming even more profitable if one of their pharmaceuticals winds up proving to be an effective treatment for a chronic illness that currently lacks any form of treatment.
